Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04861714 · ClinicalTrials.gov registry record · NA
Evaluation of Regeneten Augmentation for Subscapularis Healing After Total Shoulder Arthroplasty (RESTOR)
A NA study of Arthroplasty, Replacement, Shoulder, sponsored by Ohio State University.
- Active
- Registry status
- NA
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT04861714 is a NA study of Arthroplasty, Replacement, Shoulder that is active but no longer recruiting, run by Ohio State University. The registered enrollment target is 75 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04861714, a NA study of Arthroplasty, Replacement, Shoulder, is active but no longer recruiting, sponsored by Ohio State University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate whether augmentation of subscapularis repair with the Regeneten implant after anatomic total shoulder arthroplasty (TSA) can improve rates of subscapularis healing and improve clinical outcomes.
Conditions Studied
Interventions
- DEVICE Regeneten
- PROCEDURE Standard repair
Study Locations (1)
Ohio
- The Ohio State University Sports Medicine Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2020-07-14 |
| Est. Completion | 2027-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04861714
The ClinicalTrials.gov registry entry for NCT04861714 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arthroplasty, Replacement, Shoulder appearing as the primary indexed condition, and to 2 interventions - of which Regeneten is the first listed.
NCT04861714 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT04861714 about?
NCT04861714 is a clinical study titled "Evaluation of Regeneten Augmentation for Subscapularis Healing After Total Shoulder Arthroplasty (RESTOR)". The purpose of this study is to evaluate whether augmentation of subscapularis repair with the Regeneten implant after anatomic total shoulder arthroplasty (TSA) can improve rates of subscapularis healing and improve clinical outcomes.
What is the current status of trial NCT04861714?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 75 participants. The study started on 2020-07-14. Estimated completion is 2027-04.
What conditions does trial NCT04861714 study?
This clinical trial studies the following conditions: Arthroplasty, Replacement, Shoulder.
What interventions are being tested in trial NCT04861714?
The interventions under investigation include: Regeneten (DEVICE), Standard repair (PROCEDURE).
Who is sponsoring clinical trial NCT04861714?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04861714 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthroplasty, Replacement, Shoulder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.